Computational Biology

SimuGen is a Cambridge based biotech company founded in June 2005. The company is developing innovative predictive toxicology products, initially for the pharmaceutical industry.

SimuGen’s scientific team combines strong interdisciplinary expertise in clinical pathology, human genetics, computational biology, mathematics and software engineering.





Offering an alternative approach to toxicogenomics, SimuGen’s objective is to provide novel analytical and software tools to predict toxicity using in-vitro methods, better, faster and in a more cost-effective way than current approaches. SimuGen’s technology is proven and has been externally validated.

  Library

   Bio1nf0rm Article (pdf)

   Software Demo (flash)

   Corporate Summary (pdf)